Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan

N/ACompletedNCT02335606

Bristol-Myers Squibb213 enrolled

Overview

Abatacept Registry in Taiwan

Study Type

OBSERVATIONAL

Enrollment

213

Conditions

Rheumatoid Arthritis

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * ≥ 20 years of age * Who give informed consent * Confirmed diagnosis of RA (as defined by American College of Rheumatology revised 1987 criteria) and has ≥ 4 of the criteria listed below for ≥6 weeks before study enrollment * Who self-pay or who are reimbursed by BNHI for abatacept treatment * With latent TB or who are receiving anti-TB treatment (INH 300 mg, QD) 1 month prior to using abatacept and continuously up to a total of 9 months Willing to follow Taiwan Risk Management Plan guidelines as required by Taiwan health authorities * Are being treated with abatacept or are abatacept treatment naïve and are initiating abatacept therapy Exclusion Criteria: * Pregnant or breast feeding * With active TB * HBsAg (+)and/or Anti-HCV(+) and/or HBV DNA(+) * Have cancer (patients who were treated and have no sign of cancer for \> 10 years can be included) * Are allergic to abatacept * Enrolled in other RA clinical studies

Locations (1)

Local Institution

Taipei, Taiwan

Outcomes

Primary Outcomes

The retention rate of abatacept therapy over 24 months in RA patients under real world clinical practice in Taiwan.

Treatment retention rate is defined as the proportion of subjects who use abatacept for 24 months

Time frame: approximately 24 months